Abstract
Cancer stem cells (CSCs) are cancer cells that are responsible for initiation, progression, metastasis, and recurrence in cancer. The aim of this review was to analyze the markers for identifying of CSCs in colorectal carcinoma, as well as the prognostic and therapeutic implications of these markers in the cancer. CSCs are insensitive to the current drug regimens. In colorectal carcinoma, markers, including Nanog, Oct-4, SOX-2, Lgr-5, CD133, CD24, CD29, ALDH1, EpCAM, CD44, CD166, and CD26, are commonly used for the identification and isolation of CSCs. In addition, ALDH1, CD24, CD44, CD133, CD166, EpCAM, Lgr-5, Nanog, and SOX-2 could have clinical roles in predicting pathological stages, cancer recurrence, therapy resistance, and patients' survival in patients with colorectal carcinoma. In light of the current knowledge of CSCs in colorectal carcinoma, novel potential therapeutic strategies, such as development of monoclonal antibodies or immunotoxins and targeting various cell surface molecules in colorectal CSCs and/or components of signaling pathways, have been developed. This could open new opportunities for the better management of patients with colorectal carcinoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
